Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SAB Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for SAB Biotherapeutics, Inc.

SABS SABSW

SAB Biotherapeutics, Inc.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders. Its proprietary platform produces targeted, high-potency antibodies using genetically engineered transchromosomic cattle, enabling scalable, plasma-free manufacturing. The company focuses on autoimmune diseases like type 1 diabetes, aiming for disease-modifying therapies with improved safety, re-dosing potential, and addressing unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SAB Biotherapeutics, Inc.

1
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports Increased Operating Expenses and Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports $13.3 Million Net Income for 2025, Driven by Warrant Liabilities

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports $45.4 Million Net Income in Q3 2025, Driven by Warrant Liabilities Gain

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports $10.1 Million Net Loss in Q2 2025, Seeks Funding for Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports Zero Revenue and Increased Losses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports $34.1 Million Net Loss and Plans Phase 2b Trial for T1D Therapy

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SAB Biotherapeutics, Inc. SAB Biotherapeutics Reports Significant Financial Challenges, Net Loss, and Liquidity Concerns in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments